Cholecystokinin is up-regulated in obese mouse islets and expands β-cell mass by increasing β-cell survival

Endocrinology

Volumn 151, Issue 8, 2010, Pages 3577-3588

  Lavine, Jeremy A ^a   Raess, Philipp W ^a   Stapleton, Donald S ^a   Rabaglia, Mary E ^a   Suhonen, Joshua I ^a   Schueler, Kathryn L ^a   Koltes, James E ^a   Dawson, John A ^b   Yandell, Brian S ^b   Samuelson, Linda C ^d   Beinfeld, Margery C ^e   Belt Davis, Dawn ^a,c   Hellerstein, Marc K ^f   Keller, Mark P ^a   Attie, Alan D ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Wisconsin Madison   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e TUFTS UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ;

ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL DEATH; CELL ISOLATION; CELL SURVIVAL; DIABETOGENESIS; ENDOPLASMIC RETICULUM STRESS; FEMALE; GENE EXPRESSION; HYPERGLYCEMIA; HYPERINSULINEMIA; INNER CELL MASS; MALE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; CELL COUNT; CELL SURVIVAL; CELLS, CULTURED; CHOLECYSTOKININ; DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MICE, TRANSGENIC; OBESITY; ORGAN SIZE; UP-REGULATION;

EID: 77954896463     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0233     Document Type: Article

References (68)

1. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC 2003 β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110 (Pubitemid 36042113)
2. Klöppel G, Löhr M, Habich K, Oberholzer M, Heitz PU 1985 Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4:110-125
3. Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC 2006 Relationship between β-cell mass and fasting blood glucose concentration in humans. Diabetes Care 29:717-718
4. Keller MP, Choi Y, Wang P, Davis DB, Rabaglia ME, Oler AT, Stapleton DS, Argmann C, Schueler KL, Edwards S, Steinberg HA, Chaibub Neto E, Kleinhanz R, Turner S, Hellerstein MK, Schadt EE, Yandell BS, Kendziorski C, Attie AD 2008 A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res 18:706-716
5. Bock T, Pakkenberg B, Buschard K 2003 Increased islet volume but unchanged islet number in ob/ob mice. Diabetes 52:1716-1722 (Pubitemid 36792462)
6. Tomita T, Doull V, Pollock HG, Krizsan D 1992 Pancreatic islets of obese hyperglycemic mice (ob/ob). Pancreas 7:367-375
7. Lan H, Rabaglia ME, Stoehr JP, Nadler ST, Schueler KL, Zou F, Yandell BS, Attie AD 2003 Gene expression profiles of nondiabetic and diabetic obese mice suggest a role of hepatic lipogenic capacity in diabetes susceptibility. Diabetes 52:688-700 (Pubitemid 36323576)
8. Dufresne M, Seva C, Fourmy D 2006 Cholecystokinin and gastrin receptors. Physiol Rev 86:805-847
9. Ahrén B, Hedner P, Lundquist I 1983 Interaction of gastric inhibitory polypeptide (GIP) and cholecystokinin (CCK-8) with basal and stimulated insulin secretion in mice. Acta Endocrinol 102:96-102 (Pubitemid 13169479)
10. Fehmann HC, Göke R, Göke B, Bächle R, Wagner B, Arnold R 1991 Priming effect of glucagon-like peptide-1 (7-36) amide, glucosedependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas. Biochim Biophys Acta 1091:356-363
11. Ahrén B, Holst JJ, Efendic S 2000 Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endocrinol Metab 85:1043-1048 (Pubitemid 32269347)
12. Hildebrand P, Ensinck JW, Ketterer S, Delco F, Mossi S, Bangerter U, Beglinger C 1991 Effect of a cholecystokinin antagonist on mealstimulated insulin and pancreatic polypeptide release in humans. J Clin Endocrinol Metab 72:1123-1129 (Pubitemid 21921817)
13. Chen S, Turner S, Tsang E, Stark J, Turner H, Mahsut A, Keifer K, Goldfinger M, Hellerstein MK 2007 Measurement of pancreatic islet cell proliferation by heavy water labeling. Am J Physiol Endocrinol Metab 293:E1459-E1464
14. Kuntz E, Pinget M, Damgé P 2004 Cholecystokinin octapeptide: a potential growth factor for pancreatic β-cells in diabetic rats. JOP 5:464-475 (Pubitemid 41573849)
15. Lacourse KA, Swanberg LJ, Gillespie PJ, Rehfeld JF, Saunders TL, Samuelson LC 1999 Pancreatic function in CCK-deficient mice: adaptation to dietary protein does not require CCK. Am J Physiol 276:G1302-G1309
16. Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, Nowak NJ, Joyner A, Leblanc G, Hatten ME, Heintz N 2003 A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425:917-925
17. Rabaglia ME, Gray-Keller MP, Frey BL, Shortreed MR, Smith LM, Attie AD 2005 α-Ketoisocaproate-induced hypersecretion of insulin by islets from diabetes-susceptible mice. Am J Physiol Endocrinol Metab 289:E218-E224
18. Beinfeld MC, Meyer DK, Eskay RL, Jensen RT, Brownstein MJ 1981 The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res 212:51-57 (Pubitemid 11100783)
19. Kitagawa K, Aida C, Fujiwara H, Yagami T, Futaki S, Kogire M, Ida J, Inoue K 2001 Facile solid-phase synthesis of sulfated tyrosine-containing peptides: total synthesis of human big gastrin-II and cholecystokinin (CCK)-39. J Org Chem 66:1-10 (Pubitemid 32057833)
20. Clee SM, Yandell BS, Schueler KM, Rabaglia ME, Richards OC, Raines SM, Kabara EA, Klass DM, Mui ET, Stapleton DS, Gray-Keller MP, Young MB, Stoehr JP, Lan H, Boronenkov I, Raess PW, Flowers MT, Attie AD 2006 Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. Nat Genet 38:688-693
21. 2H2O labeling of the deoxyribose moiety of DNA. Proc Natl Acad Sci USA 99:15345-15350
22. Lilla V, Webb G, Rickenbach K, Maturana A, Steiner DF, Halban PA, Irminger JC 2003 Differential gene expression in well-regulated and dysregulated pancreatic β-cell (MIN6) sublines. Endocrinology 144:1368-1379 (Pubitemid 36428479)
23. Beinfeld MC 2003 Biosynthesis and processing of pro CCK: recent progress and future challenges. Life Sci 72:747-757
24. Whited KL, Thao D, Lloyd KC, Kopin AS, Raybould HE 2006 Targeted disruption of the murine CCK1 receptor gene reduces intestinal lipid-induced feedback inhibition of gastric function. Am J Physiol 291:G156-G162
25. Mandrup-Poulsen T 2003 Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol 66:1433-1440 (Pubitemid 38373330)
26. Lee SC, Pervaiz S 2007 Apoptosis in the pathophysiology of diabetes mellitus. Int J Biochem Cell Biol 39:497-504
27. Eizirik DL, Cardozo AK, Cnop M 2008 The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 29:42-61 (Pubitemid 351252746)
28. Scheuner D, Kaufman RJ 2008 The unfolded protein response: a pathway that links insulin demand with β-cell failure and diabetes. Endocr Rev 29:317-333 (Pubitemid 351679702)
29. 2+, leading to induction of endoplasmic reticulum stress in pancreatic β-cells. Diabetes 54:452-461
30. Shimizu K, Kato Y, Shiratori K, Ding Y, Song Y, Furlanetto R, Chang TM, Watanabe S, Hayashi N, Kobayashi M, Chey WY 1998 Evidence for the existence of CCK-producing cells in rat pancreatic islets. Endocrinology 139:389-396 (Pubitemid 28166333)
31. Dreja T, Jovanovic Z, Rasche A, Kluge R, Herwig R, Tung YC, Joost HG, Yeo GS, Al-Hasani H 2010 Diet-induced gene expression of isolated pancreatic islets from a polygenic mouse model of the metabolic syndrome. Diabetologia 53:309-320
32. Rehfeld JF 2006 The endoproteolytic maturation of progastrin and procholecystokinin. J Mol Med 84:544-550
33. Rouillé Y, Westermark G, Martin SK, Steiner DF 1994 Proglucagon is processed to glucagon by prohormone convertase PC2 in αTC1-6 cells. Proc Natl Acad Sci USA 91:3242-3246 (Pubitemid 24130212)
34. Bourassa J, Lainé J, Kruse ML, Gagnon MC, Calvo E, Morisset J 1999 Ontogeny and species differences in the pancreatic expression and localization of the CCK(A) receptors. Biochem Biophys Res Commun 260:820-828 (Pubitemid 29371133)
35. Julien S, Lainé J, Morisset J 2004 The rat pancreatic islets: a reliable tool to study islet responses to cholecystokinin receptor occupation. Regul Pept 121:73-81 (Pubitemid 38901064)
36. Kageyama H, Kita T, Horie S, Takenoya F, Funahashi H, Kato S, Hirayama M, Young Lee E, Sakurai J, Inoue S, Shioda S 2005 Immunohistochemical analysis of cholecystokinin A receptor distribution in the rat pancreas. Regul Pept 126:137-143 (Pubitemid 40037756)
37. Morisset J, Wong H, Walsh JH, Lainé J, Bourassa J 2000 Pancreatic CCK(B) receptors: their potential roles in somatostatin release and δ-cell proliferation. Am J Physiol 279:G148-G156
38. Saillan-Barreau C, Dufresne M, Clerc P, Sanchez D, Corominola H, Moriscot C, Guy-Crotte O, Escrieut C, Vaysse N, Gomis R, Tarasova N, Fourmy D 1999 Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes 48:2015-2021
39. Boushey RP, Abadir A, Flamez D, Baggio LL, Li Y, Berger V, Marshall BA, Finegood D, Wang TC, Schuit F, Drucker DJ 2003 Hypoglycemia, defective islet glucagon secretion, but normal islet mass in mice with a disruption of the gastrin gene. Gastroenterology 125:1164-1174
40. Kopin AS, Mathes WF, McBride EW, Nguyen M, Al-Haider W, Schmitz F, Bonner-Weir S, Kanarek R, Beinborn M 1999 The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest 103:383-391
41. Langhans N, Rindi G, Chiu M, Rehfeld JF, Ardman B, Beinborn M, Kopin AS 1997 Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology 112:280-286
42. Takiguchi S, Takata Y, Funakoshi A, Miyasaka K, Kataoka K, Fujimura Y, Goto T, Kono A 1997 Disrupted cholecystokinin type-A receptor (CCKAR) gene in OLETF rats. Gene 197:169-175 (Pubitemid 27399890)
43. Huang Q, Bu S, Yu Y, Guo Z, Ghatnekar G, Bu M, Yang L, Lu B, Feng Z, Liu S, Wang F 2007 Diazoxide prevents diabetes through inhibiting pancreatic β-cells from apoptosis via Bcl-2/Bax rate and p38-β mitogen-activated protein kinase. Endocrinology 148:81-91
44. Zhao J, Zhang N, He M, Yang Z, Tong W, Wang Q, Hu R 2008 Increased β-cell apoptosis and impaired insulin signaling pathway contributes to the onset of diabetes in OLETF rats. Cell Physiol Biochem 21:445-454 (Pubitemid 351620298)
45. Rooman I, Bouwens L 2004 Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57BL6/J mice treated with alloxan. Diabetologia 47:259-265 (Pubitemid 38315362)
46. Suarez-Pinzon WL, Lakey JR, Rabinovitch A 2008 Combination therapy with glucagon-like peptide-1 and gastrin induces β-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant 17:631-640
47. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A 2008 Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57:3281-3288
48. Suarez-Pinzon WL, Yan Y, Power R, Brand SJ, Rabinovitch A 2005 Combination therapy with epidermal growth factor and gastrin increases β-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 54:2596-2601 (Pubitemid 41233580)
49. Zucker KA, Adrian TE, Bilchik AJ, Modlin IM 1989 Effects of the CCK receptor antagonist L364,718 on pancreatic growth in adult and developing animals. Am J Physiol 257:G511-G516
50. Wisner Jr JR, McLaughlin RE, Rich KA, Ozawa S, Renner IG 1988 Effects of L-364,718, a new cholecystokinin receptor antagonist, on camostate-induced growth of the rat pancreas. Gastroenterology 94:109-113 (Pubitemid 18029766)
51. Carrillo J, García-Aragoncillo E, Azorín D, Agra N, Sastre A, González-Mediero I, García-Miguel P, Pestaña A, Gallego S, Segura D, Alonso J 2007 Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth. Clin Cancer Res 13:2429-2440
52. Carrillo J, Agra N, Fernández N, Pestaña A, Alonso J 2009 Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth. Anticancer Drugs 20:527-533
53. Shima K, Zhu M, Mizuno A 1999 Pathoetiology and prevention of NIDDM lessons from the OLETF rat. J Med Invest 46:121-129
54. Lavine JA, Raess PW, Davis DB, Rabaglia ME, Presley BK, Keller MP, Beinfeld MC, Kopin AS, Newgard CB, Attie AD 2010 Contamination with E1A-positive wild-type adenovirus accounts for species-specific stimulation of islet cell proliferation by CCK: a cautionary note. Mol Endocrinol 24:464-467
55. Cheung GW, Kokorovic A, Lam CK, Chari M, Lam TK 2009 Intestinal cholecystokinin controls glucose production through a neuronal network. Cell Metab 10:99-109
56. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y 1999 Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96:14843-14847
57. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ 1996 Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2:1254-1258
58. Li L, El-Kholy W, Rhodes CJ, Brubaker PL 2005 Glucagon-like peptide-1 protects β-cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 48:1339-1349 (Pubitemid 41186100)
59. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ 2003 Glucagon-like peptide-1 receptor signaling modulates β-cell apoptosis. J Biol Chem 278:471-478 (Pubitemid 36043598)
60. Widenmaier SB, Ao Z, Kim SJ, Warnock G, McIntosh CH 2009 Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the β-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. J Biol Chem 284:30372-30382
61. Wideman RD, Yu IL, Webber TD, Verchere CB, Johnson JD, Cheung AT, Kieffer TJ 2006 Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc Natl Acad Sci USA 103:13468-13473
62. Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, Pipeleers D, Ling Z, Drucker DJ 2006 GLP-1 receptor activation improves β-cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 4:391-406 (Pubitemid 44752565)
63. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y 2002 Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738-742
64. Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, Harriott P, O'harte FP, Flatt PR 2005 Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54:2436-2446
65. Ling Z, Wu D, Zambre Y, Flamez D, Drucker DJ, Pipeleers DG, Schuit FC 2001 Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 438:382-387
66. Scrocchi LA, Hill ME, Saleh J, Perkins B, Drucker DJ 2000 Elimination of glucagon-like peptide1Rsignaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. Diabetes 49:1552-1560
67. Anini Y, Brubaker PL 2003 Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 52:252-259
68. Baggio LL, Drucker DJ 2007 Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157